Pluri Inc. announced that its CDMO division (PluriCDMO?) has signed a manufacturing agreement with Remedy Cell Ltd, an innovative, biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions. PluriCDMO? will support Remedy Cell?s production team in the manufacturing of a clinical-grade Working Cell Bank (WCB) and GMP batches of Remedy Cell?s drug candidate RC-0315, derived from mesenchymal stem cells, towards the launch of their Phase Ib clinical trial for the treatment of Idiopathic Pulmonary Fibrosis (IPF), a lethal, complex, progressive interstitial lung disorder with a median survival of 3.8 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
5.89 USD | +5.18% | +5.18% | +27.05% |
May. 02 | Pluri Inc. Launches Novel Immunotherapy Platform for Solid Tumor Cancer Treatment | CI |
May. 02 | Pluri Inc. Announces Appointments to Its Scientific Advisory Board | CI |
1st Jan change | Capi. | |
---|---|---|
+27.05% | 31.74M | |
+21.74% | 46.4B | |
-0.97% | 41.75B | |
+48.83% | 41.37B | |
-3.52% | 29.71B | |
+11.12% | 26.01B | |
-19.37% | 19.52B | |
+31.18% | 12.43B | |
-0.04% | 12.13B | |
+0.39% | 12.18B |
- Stock Market
- Equities
- PLUR Stock
- News Pluri Inc.
- Pluri Selected as Cdmo by Remedy Cell for Cell-Derived Cell-Free Drug Manufacturing